MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

Noro, Rintaro; Seike, Masahiro; Zou, Fenfei; Soeno, Chie; Matsuda, Kuniko; Sugano, Teppei; Nishijima, Nobuhiko; Matsumoto, Masaru; Kitamura, Kazuhiro; Kosaihira, Seiji; Minegishi, Yuji; Yoshimura, Akinobu; Kubota, Kaoru; Gemma, Akihiko

doi:10.1186/s12885-015-1019-1

Table 1 EGFR and MET gene status of 35 lung adenocarcinoma cases

From: MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

						Before Gefitinib treatments			At Gefitinib treatment failure
Case No ^b	Smoking	Staging	Gefitinib response	EGFR mutation type	MET FISH status	MET IHC	EGFR mutation type	MET FISH status	PFS(Months)	OS(Months)
1	-	IV	PR	Ex19 deletion	++	+	Ex19 deletion	++	7.3	15
2	-	IV	PR	Ex19 deletion	+		Not detected	+	7.6	11.9
3	+	Relapse	PR	Ex19 deletion	+		Ex19 deletion/T790M	+	18.5	34.4
4	-	Relapse	PR	Ex19 deletion	+	-			16.6	20.9
5	+	IIIA	PR	Ex19 deletion	+				8.5	20
6	-	Relapse	PR	Ex19 deletion	+				1.8	1.8
7	-	IV	PD	L858R	+		L858R	+	13.6	15
8	+	Relapse	PD	L858R	+	+			2.7	8.8
9	-	Relapse	CR	L858R	+	-			13	28.4
10	-	Relapse	PR	L858R	+	-			7.6	11.2
11	+	IV	PR	L858R	+				5.7	7.3
12	+	IV	PR	Ex19 deletion	-		Ex19 deletion	-	13.9	21
13	+	IV	PR	Ex19 deletion	-		Ex19 deletion	-	10.4	36.4
14	-	IV	PR	Ex19 deletion	-		Ex19 deletion	-	24.7	31.1
15	-	Relapse	PR	Ex19 deletion	-	-	Ex19 deletion/T790M	-	28.4	33.8
16	-	Relapse	PR	Ex19 deletion	-	-			11.1	21
17	+	Relapse	PR	Ex19 deletion	-	-			24.4	24.4
18	-	IIIA	PR	Ex19 deletion	-				6.5	14.9
19	-	IIIB	PR	Ex19 deletion	-				29.8	38.2
20	+	IIIB	PR	Ex19 deletion	-				41.5	48.6
21	-	IV	PR	Ex19 deletion	-				13.2	26.7
22	+	IV	PR	Ex19 deletion	-				17.1	17.1
23	-	IV	PR	Ex19 deletion	-				13.3	19.2
24	-	IV	PR	Ex19 deletion	-				21.8	25.5
25	-	IV	PR	Ex19 deletion	-				15.2	31.6
26	-	IV	SD	Ex19 deletion	-				3.4	26.8
27	+	Relapse	PR	Ex19 deletion	-				18.7	50.2
28	+	Relapse	PR	Ex19 deletion	-				15.9	20.2
29	-	Relapse	PR	Ex19 deletion	-				12.1	15
30	+	Relapse	SD	Ex19 deletion	-				11.1	13.6
31	-	Relapse	PR	L858R	-		L858R	-	58.7	123.5
32	-	IV	PR	L858R	-	-			4.5	4.5
33	+	Relapse	PR	L858R	-				15.5	16.7
34	+	Relapse	PR	L858R	-				13.5	13.5
35	-	Relapse	PR	L858R	-				7.1	7.1

MET FISH status; ++Amplification, +High polysomy.
^bPatient identifiers have been removed and relabeled.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us